Cargando…

Tisotumab Vedotin Safety and Tolerability in Clinical Practice: Managing Adverse Events

Tisotumab vedotin-tftv, an antibody-drug conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, demonstrated clinically meaningful and durable responses with a manageable safety profile in the pivotal ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arn, Courtney R., Halla, Kimberly J., Gill, Sally
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press LLC 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062530/ https://www.ncbi.nlm.nih.gov/pubmed/37009403 http://dx.doi.org/10.6004/jadpro.2023.14.2.4

Ejemplares similares

Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors
por: Passey, Chaitali, et al.
Publicado: (2023)

Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors
por: Gibiansky, Leonid, et al.
Publicado: (2022)

Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data
por: Agostinelli, Veronica, et al.
Publicado: (2023)

Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study
por: Yonemori, Kan, et al.
Publicado: (2022)

Brentuximab vedotin: clinical updates and practical guidance
por: Yi, Jun Ho, et al.
Publicado: (2017)

Characterization of cutaneous adverse events to enfortumab vedotin: A retrospective case-control study
por: Shahin, Ahmad, et al.
Publicado: (2022)

Idelalisib: Practical Tools for Identifying and Managing Adverse Events in Clinical Practice
por: Driscoll, Nancy
Publicado: (2016)

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
por: Heinzerling, Lucie, et al.
Publicado: (2019)

Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Brentuximab Vedotin Infusion Reaction Management: A Case Study
por: Comer, Holly, et al.
Publicado: (2017)

Brentuximab Vedotin
Publicado: (2012)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin
por: Lacouture, Mario E, et al.
Publicado: (2022)

Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
por: Wu, Susan Y., et al.
Publicado: (2023)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Regarding “Management of Dermatologic Events Associated with the Nectin-4–directed Antibody-Drug Conjugate Enfortumab Vedotin”
por: Ingen-Housz-Oro, Saskia, et al.
Publicado: (2022)

Clinical development and management of adverse events associated with FGFR inhibitors
por: Subbiah, Vivek, et al.
Publicado: (2023)

Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events
por: Gu, Stephanie L., et al.
Publicado: (2023)

Enfortumab Vedotin-Induced Toxic Epidermal Necrolysis: A Rare Fatal Adverse Reaction
por: Bansal, Aditi, et al.
Publicado: (2022)

Time‐to‐Event Analysis of Polatuzumab Vedotin‐Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens
por: Lu, D, et al.
Publicado: (2017)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System
por: Yang, Hui, et al.
Publicado: (2022)

Adoptive T-cell therapy: adverse events and safety switches
por: Tey, Siok-Keen
Publicado: (2014)

Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma
por: Gerendash, Benjamin S, et al.
Publicado: (2017)

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
por: O’Brien, Susan M., et al.
Publicado: (2021)

Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022)

Drug extravasation with Enfortumab vedotin
por: Grant, Christopher Ryan, et al.
Publicado: (2023)

Adverse Events of Oncologic Immunotherapy and Their Management
por: Barber, Fedricker Diane
Publicado: (2019)

Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies
por: Pincez, Thomas, et al.
Publicado: (2020)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2014)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
por: Moussa, Mohamad, et al.
Publicado: (2021)

Nintedanib in advanced NSCLC: management of adverse events
por: Lemmens, Liesbeth
Publicado: (2016)

CAR T-Cell Therapy: Adverse Events and Management
por: Adkins, Sherry
Publicado: (2019)

Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide
por: Davies, Mark, et al.
Publicado: (2017)

Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events
por: Davies, Marianne, et al.
Publicado: (2017)

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
por: Fahey, Catherine C., et al.
Publicado: (2023)

Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
por: Tsang, Vivian
Publicado: (2012)

Brentuximab vedotin: axonal microtubule's Apollyon
por: Mariotto, S, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_b1qpcvvjliqcp0h393j3ccq1j4